Abstract
As an important enteric neurotransmitter, therole of dopamine as a mitotic inhibitor as well as aprotective factor of epithelial cells of stomach andcolon indicates its significance in malignant growth of gastrointestinal tract. Our previous resultshave shown significant alteration of dopamine receptorsin human malignant stomach tissues. The presentexperiments, therefore, evaluate DA content, itsreceptor expression, and its second-messenger cAMP inhuman malignant colon tissues to evaluate its role.Results demonstrate a significant decrease of dopaminecontent, its receptor expression, and itssecond-messenger cAMP in malignant tissues of human colon. Theseresults may provide insight into the role of dopamine asan enteric neurotransmitter on malignant growth of humancolon and may also suggest a therapeutic approach targeting dopamine receptors and itssignal transduction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Tutton PJ, Barkala DH: Biogenic Amines as regulator of the proliferative activity of normal and neoplastic cells. Anticancer Res 17:1–12, 1987
Wegner IC, Dawiris RR, Grond C, Teuche rt-Noodte: Dopamine and the regulation of cell proliferation in gerbil pyloric mucosa. Life Sci 60:2005–2011, 1997
MacNaughton W, Wallace JL: A role for dopamine as an endogenous protective factor in the rat stomach. Gastroenterology 96:972–980, 1989
Shibata MA, Hirose M, Yumuda M, Tatematsu M, Uwngawa S, Nohuyuki I: Epithelial cell proliferation in rat forestomach and glandular stomach mucosa induced by catechols and analogs dihydroxy benzenes. Carcinogenesis 11:997–1000, 1990
Glavin GB, Szabo S: Dopamine in gastrointestinal disease. Dig Dis Sci 35:1153–1161, 1990
Glavin GB, Hall AM: Central and peripheral dopamine DAI receptor modulation of gastric secretion and experimental gastric mucosal injury. Gen Pharmacol 26:1277–1279, 1995
Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG: Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37:165–216, 1985
Hernandez DE, Mason GA, Walker CH, Valenzuela JE: Dopamine receptors in human gastrointestinal mucosa. Life Sci 41:2717–2723, 1987
Haskel Y, Hanai M: Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanism. Dig Dis Sci 39:2364–2367, 1994
Eisenhoffer G, Aneman A, Friberg P, Hooper D, Fandriks L, Lonroth L, Hunyady B, Mezey E: Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metabol 82:3864–3871, 1997
Basu S, Dasgupta PS: Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci 42:1260–1264, 1997
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein me asurements with Folin phenol reagent. J Biol Chem 193:265–275, 1951
Grollman A, Grollman EF: In Pharmacology and Therapeutics. Philadelphia, Lea and Febiger, 1970, 270 pp
Singaram C, Asharf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley MME: Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346:861–864, 1995
Back N, Ahonen M, Soinila S, Kivilaakso E, Kivilaoto T: Catecholamine synthesizing enzyme s in the rat stomach. Histochem Cell Biol 104:63–67, 1995
Civelli O, Bunzow JR, Grandy DK: Molecular diversity of dopamine receptors. Annu Rev Pharmacol Toxicol 32:281–307, 1993
Kusunoki M, Taniyama K, Tanaka C: Dopamine regulation of (3H) acetylcholine re lease from guinea pig stomach. J Pharmacol Exp Ther 234:713–716, 1985
Gurukalo VK, Volfson NJ: Nicotine influences upon the development of stomach tumor. Arch Gesh Wulsforch 52:259–263, 1982
Ve lazquez OC, Zhou D, Scoto RM, Jabber A, Choi J, Lederer HM, Rombean JL: In vivo crypt surface hyperproliferation is decrease d by butyrate and increase d by deoxycholate in normal rat colon: Associated in vivo effects on C-fos and C-Jun expression. J Parenter Enteral Nutr 20:243–247, 1996
Miller SC: Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J Neurochem 54:1453–1456, 1990
Robertson HA, Paul ML, Moratella R, Graybial AM: Expression of immediate early gene c-fos in basal ganglia, induction by dopaminergic drugs. Can J Neurol Sci 18:380–384, 1991
Cheranavsky AC, Valerant AV, Burdman JA: Haloperidol and estrogen induce c-myc and c-fos expression in the anterior pituitary gland of rat. Neurol Res 15:339–342, 1993
Enjalbart A, Bockaert J: Pharmacological characterization of the D2 dopaminergic receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 23:576–584, 1983
Gamet L, Murat JC, Remaury A, Rmesy C, Valet H, Paris H, Denis-Pouseviel C: Vasoactive intestinal peptide and forkskolin regulate proliferation of the HT 29 human colon adenocarcinoma cell line. J Cell Physiol 150:501–509, 1992
Tagliaferri P, Katsaros D, Clair T, Ally S, Tortora G, Neckers L, Rubalcava B, Parandoosh Y, Chang A, Revankar GR: Synergistic inhibition of growth of breast and colon human cancer cell lines by site selective cAMP analogues. Can Res 48:1642–1650, 1988
Bold RJ, Warren RE, Ishizuka J, Cho-Chung YS, Townsend CM, Thomson SC: Experimental genetherapy of human colon cancer. Surgery 116:189–195, 1994
Rights and permissions
About this article
Cite this article
Basu, S., Dasgupta, P.S. Decreased Dopamine Receptor Expression and Its Second-Messenger cAMP in Malignant Human Colon Tissue. Dig Dis Sci 44, 916–921 (1999). https://doi.org/10.1023/A:1026644110737
Issue Date:
DOI: https://doi.org/10.1023/A:1026644110737